Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.69 as of 2026-10-06T18:08:39.085Z.
Consensus retrieved: 2026-10-06T14:12:39.120Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:08:39.085Z.
Quote observation: 2026-10-06T18:05:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7123ab057bb1841ee835f9c71551e031ef341e3ba9317ad50f2164e9d5c136ac
Forward PE Ratio (18.69) = Dated Quote Price ($2.69) / Consensus Forward EPS ($0.14)
FORWARD PE RATIO
18.69
SECTOR MEDIAN · HEALTHCARE
19.85
median of 189 covered companies
CURRENT VS SECTOR MEDIAN
-5.84%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$214.64M
Forward PE Ratio
18.69
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.64M | 18.69 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.92M | N/A |
| Compugen Ltd. (CGEN)vs › | $211.80M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.51M | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.24M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.55M | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.75M | 21.06 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $207.51M | N/A |
| Profound Medical Corp. (PROF)vs › | $223.29M | N/A |
Trailing P/E
14.5
reported TTM EPS
Forward P/E
18.7
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.14 implies -26.3% EPS decline vs the reported trailing $0.19.
At the dated quote price of $2.69, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.14 | $0.10 – $0.18 | 3 | 18.7x |
| 2027-12-31 | $0.15 | $0.11 – $0.21 | 2 | 17.4x |
| 2028-12-31 | $0.25 | $0.24 – $0.26 | 2 | 10.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
